March 31, 2008 – KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase 1/2 clinical trial of KB001, a Humaneered™, high-affinity antibody fragment that KaloBios is developing for the treatment of P. aeruginosa infections. The trial is being conducted in conjunction with the Cystic Fibrosis Foundation and its affiliated organizations.The blinded, placebo-controlled trial, which is being conducted at over 10 sites across the United States, will enroll up to 48 patients with cystic fibrosis who will receive either one of two dose levels of KB001 or placebo. Endpoints for the trial include safety, reduction of P. aeruginosa bacteria, and inflammatory markers... KaloBios' Press Release -
